Recent Updates — WST
West Pharmaceutical Services reported third-quarter 2026 net sales of $874.5 million, an 8.7% increase from the prior year period, driven by strong performance in its High-Value Product Components business which grew 19.7%. Diluted earnings per share rose to $3.02, up 57.3%, while adjusted diluted EPS increased 35.7% to $2.66. The company raised its full-year 2026 net sales guidance to a range of $3.41 billion to $3.42 billion and adjusted diluted EPS guidance to $9.38-$9.48, citing robust execution and margin expansion. West repurchased $231 million of stock in the quarter and declared a fourth-quarter dividend of $0.26 per share. The company operates as a leading provider of innovative injectable solutions and services for pharmaceutical companies.
West Pharmaceutical Services entered into a new five-year credit agreement providing for up to $750 million in revolving commitments and an initial $200 million term loan. The company used proceeds from the new borrowing to fully repay and terminate its existing 2019 Credit Agreement, which had $130 million outstanding. The facility includes provisions for letters of credit and swing line loans, with interest rates tied to SOFR or base rates plus applicable margins based on leverage ratios. West Pharmaceutical Services manufactures packaging and delivery systems for the pharmaceutical industry.
West Pharmaceutical Services, Inc. reported second-quarter 2026 results with net sales of $872.3 million, a 13.8% increase compared to the prior year. Diluted earnings per share of $2.15 and adjusted-diluted EPS of $2.37 both increased year-over-year. Due to strong performance, the company is raising its full-year 2026 net sales guidance to a range of $3.345 billion to $3.380 billion and adjusted-diluted EPS guidance to $8.85 to $9.05. West Pharmaceutical Services, Inc. is a provider of injectable solutions and services for the pharmaceutical industry.
West Pharmaceutical Services, Inc. and Daikyo Seiko, Ltd. entered into an Amended and Restated Technology Exchange and Crosslicense Agreement and two Distributorship Agreements effective July 14, 2026. The agreements permit the parties to share know-how and license patents and trademarks for pharmaceutical packaging and delivery products like vials, syringes, and cartridges. West maintains a 49% ownership interest in Daikyo. The agreements have a 10-year term. West Pharmaceutical Services, Inc. provides drug delivery systems and components for the pharmaceutical industry.